Physician profile
Jacqueline Fox
NPI 1447875430
$5,183.65
in general payments reported to CMS, 2019-2025
21 companies · $726 in 2025
The $726 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $473 · 2022: $861 · 2023: $1,341 · 2024: $1,782 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,712.35 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,173.56 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $579.07 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $521.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $274.84 | 2023-2025 | Rexulti, Jynarque, Abilify Maintena |
| Pfizer INC. | $165.74 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $130.82 | 2024 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $93.55 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $88.15 | 2024-2025 | Ingrezza |
| Sanofi Pasteur INC. | $70.24 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $54.74 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Vbi Vaccine (Delaware) INC. | $51.64 | 2022 | |
| Lucid Diagnostics INC. | $46.85 | 2023-2024 | |
| Esperion Therapeutics, INC. | $46.03 | 2022-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $43.83 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $36.27 | 2022-2023 | Gvoke Hypopen |
| Cequr Corporation | $23.36 | 2025 | Cequr Simplicity |
| Hologic Sales and Service, LLC | $20.33 | 2022 | |
| Lundbeck LLC | $19.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.92 | 2022 | |
| Abbvie INC. | $14.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.